Figure 3From: Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinibTTP and OS by median maximal percent change in plasma protein concentration through C2D28. (A) TTP by sKIT concentration. (B) OS by sKIT concentration. (C) TTP by VEGF-A concentration. (D) OS by VEGF-A concentration. C, cycle; D, day; OS, overall survival; sKIT, soluble KIT; TTP, time to tumor progression; VEGF, vascular endothelial growth factor.Back to article page